Immunogenicity of a Fusion Protein Containing Immunodominant Epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in Mice and Active TB Infection

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  de Sousa, Eduardo Martins ^a   da Costa, Adeliane Castro ^a   Trentini, Monalisa Martins ^a   de Araújo Filho, João Alves ^a   Kipnis, André ^a   Junqueira Kipnis, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN 85 COMPLEX ANTIGEN MPT51 HEAT SHOCK PROTEIN FUSION PROTEIN; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M; LIPOSOME; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DRUG FORMULATION; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; SPLEEN; TISSUE DISTRIBUTION; TUBERCULOSIS;

ADULT; AGED; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS;

MUS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 84868138142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047781     Document Type: Article

References (54)

1. Kaufmann SH, (2000) Is the development of a new tuberculosis vaccine possible? Nat Med 6: 955-960.
2. WHO (2011) Global tuberculosis control: WHO report 2011.
3. Secretaria de Vigilância em Saúde - Ministério da Saúde, Brasil (2012) Boletim Epidemiológico. Especial Tuberculose. Available:http://portal.saude.gov.br/portal/arquivos/pdf/bolepi_v43_especial_tb_correto.pdf. Accessed 2012 May 02.
4. Connell DW, Berry M, Cooke G, Kon OM (2011) Update on tuberculosis.
5. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, et al. (2005) Enzyme-linked Immunospot and Tuberculin Skin Testing to Detect Latent Tuberculosis Infection. Am J Respir Crit Care Med 172: 1161-1168.
6. Menzies D, Pai M, Comstock G, (2007) Meta-analysis: New tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. Ann Intern Med 146: 340-354.
7. Lienhardt C, Fielding K, Hane AA, Niang A, Ndao CT, et al. (2010) Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 5: e10508.
8. Bodmer T, Ströhle A, (2012) Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test. J Vis Exp 9: 3547.
9. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal MP, et al. (2012) Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J. [Epub ahead of print].
10. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, et al. (2012) The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based analysis. AIDS. [Epub ahead of print].
11. Almeida CMC, Vasconcelos Jr AC, Kipnis A, Andrade AL, Junqueira-Kipnis AP, (2008) Humoral immune responses of tuberculosis patients in Brazil indicate recognition of Mycobacterium tuberculosis MPT-51 and GlcB. Clin Vaccine Immunol 15: 579-81.
12. Reis MCG, Rabahi MF, Kipnis A, Junqueira-Kipnis AP, (2009) Health care workers humoral immune response against GLcB, MPT51 and HSPX from Mycobacterium tuberculosis. Braz J Infect Dis 13: 417-421.
13. Reis MC, Silva BD, Sousa EM, Junqueira-Kipnis AP, (2011) Role of antibodies reactive to HspX in discriminating pulmonary tuberculosis contacts with high risk of developing active disease. Braz J Infect Dis 15: 617-8.
14. Yuan Y, Crane DD, Barry CE 3rd, (1996) Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 178: 4484-4492.
15. Shi C, Chen L, Chen Z, Zhang Y, Zhou Z, et al. (2010) Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 28: 5237-44.
16. Backus KM, Boshoff HI, Barry CS, Boutureira O, Patel MK, et al. (2011) Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nat Chem Biol 7: 228-35.
17. Armitige LY, Jagannath C, Wanger AR, Norris SJ, (2000) Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 68: 767-78.
18. Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, et al. (2006) Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 177: 1780-5.
19. Araújo-Filho JA, Vasconcelos AC, Sousa EM, Kipnis A, Ribeiro E, et al. (2008) Cellular responses to MPT-51, GlcB and ESAT-6 among MDR-TB and active tuberculosis patients in Brazil. Tuberculosis 88: 474-481.
20. Puech V, Guilhot C, Perez E, Tropis M, Armitige LY, et al. (2002) Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol Microbiol 44: 1109-1122.
21. D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, et al. (2003) Mapping of murine Th1 helper T-Cell epitopes of mycolyltransferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71: 483-493.
22. Kumar G, Dagur PK, Singh M, Yadav VS, Dayal R, et al. (2008) Diagnostic potential of Ag85C in comparison to various secretory antigens for childhood tuberculosis. Scand J Immunol 68: 177-183.
23. Fundação Nacional de Saúde - Ministério da Saúde, Brasil (2002) Tuberculose, Guia de Vigilância Epidemilógica. Available: http://http://bvsms.saude.gov.br/bvs/publicacoes/manual_tuberculose.pdf. Accessed 2012 Feb 05.
24. Maassen C, Boersma W, Holten-Neelen C, Claassen E, Laman J, (2003) Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine 21: 2751-7.
25. Flynn JL, Chan J, (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
26. Li Q, Yu H, Zhang Y, Wang B, Jiang W, et al. (2011) Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol 73: 568-76.
27. Niu H, Hu L, Li Q, Da Z, Wang B, et al. (2011) Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 29: 9451-8.
28. Hoft DF, (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372: 164-75.
29. Feng L, Li L, Liu Y, Qiao D, Li Q, et al. (2011) B lymphocytes that migrate to tuberculous pleural fluid via the SDF-1/CXCR4 axis actively respond to antigens specific for Mycobacterium tuberculosis. Eur J Immunol 41: 3261-9.
30. Thakurdas SM, Hasan Z, Hussain R, (2004) IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells. Clin Exp Immunol 136: 320-7.
31. Torrado E, Cooper AM, (2011) What do we really know about how CD4 T cells control Mycobacterium tuberculosis? PLoS Pathog 7: e1002196.
32. Orme IM, (2011) Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol 6: 161-77.
33. Flynn JL, (2004) Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84: 93-101.
34. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, et al. (2001) The NOS2 locus confers protection in mice against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis. Infect Immun 69: 7711-7.
35. Oslen AW, Andersen P, (2003) A novel TB vaccine: strategies to combat a complex pathogen. Immumol Lett 85: 207-21.
36. Bandelac A, Medzhitov R, (2002) Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 195: F19-23.
37. Delogu G, Fadda G, (2009) The quest for a new vaccine against tuberculosis. J Infect Dev Ctries 3: 5-15.
38. Petrovsky N, Aguilar JC, (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82: 488-96.
39. Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E (2012) Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release. Epub ahead of print.
40. Chen CH, Lin YL, He PJ, Lin CM, Chiu YH, et al. (2012) Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int J Nanomedicine 7: 607-21.
41. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, et al. (2010) A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 53: 53ra74.
42. Jeon BY, Kim SC, Eum SY, Cho SN, (2011) The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. Microbes Infect 13: 284-90.
43. Uto T, Tsujimura K, Uchijima M, Seto S, Nagata T, et al. (2011) A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70. FEMS Immunol Med Microbiol 6: 189-96.
44. Shin AR, Shin SJ, Lee KS, Eom SH, Lee SS, et al. (2008) Improved sensitivity of diagnosis of tuberculosis in patients in Korea via a cocktail enzyme-linked immunosorbent assay containing the abundantly expressed antigens of the K strain of Mycobacterium tuberculosis. Clin Vac Immunol 15: 1788-1795.
45. World Health Organization (2011) Tuberculosis Serodiagnostic Tests Policy Statement. www.who.int/tb. Accessed 2012 Jan 02.
46. Samanich KM, Keen MA, Vissa VD, Harder JD, Spencer JS, et al. (2000) Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol 4: 662-8.
47. Wu L, Zhang M, Sun M, Jia B, Wang X, (2011) Humoural immune responses to a recombinant 16-kDa-38-kDa-ESAT-6 mycobacterial antigen in tuberculosis. J Int Med Res 39: 514-21.
48. Kashyap RS, Saha SM, Nagdev KJ, Kelkar SS, Purohit HJ, et al. (2010) Diagnostic Markers for Tuberculosis Ascites: A Preliminary Study. Biomarker Insights 5: 87-94.
49. Wu X, Yang Y, Zhang J, Li B, Liang Y, et al. (2010) Humoral Immune Responses against the Mycobacterium tuberculosis 38-Kilodalton, MTB48, and CFP-10/ESAT-6 Antigens in Tuberculosis. CVI 17: 372-375.
50. Margotto PR (2010) Curva ROC como fazer e interpretar no SPSS. www.paulomargotto.com.bt. Accessed 2011 Dec 10.
51. Menzies D, (2012) Hammering the point home: serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India. EBM 17: 58-59.
52. Lourembam SD, Baruah S, (2012) Antibody response to allelic variants of 19 kDa fragment of MSP-1: Recognition of a variant and protection associated with ethnicity in Assam, India. Vaccine 17: 767-73.
53. Glatman-Freedman A, Casadevall A, (1998) Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11: 514-32.
54. Adekambi T, Ibegbu CC, Kalokhe AS, Yu T, Ray SM, et al. (2012) Distinct Effector Memory CD4(+) T Cell Signatures in Latent Mycobacterium tuberculosis Infection, BCG Vaccination and Clinically Resolved Tuberculosis. PLoSOne 7: e36046.